

Notice of References Cited	Application/Control No. 10/772,235	Applicant(s)/Patent Under Reexamination LI ET AL.	
	Examiner Zachary C. Tucker	Art Unit 1624	Page 1 of 3

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Griffin et al, "The role of inhibitors of poly(ADP-ribose) polymerase as resistance-modifying agents in cancer therapy" Biochemie, vol. 77, pages 408-422 (1995).
	V	Bowman et al, "Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro" British Journal of Cancer, vol. 84(1), pages 106-112 (2001).
	W	Virag and Szabo, "The Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitors" Pharmacological Reviews, vol. 54, pages 375-429 (2002).
	X	Cosi, "New inhibitors of poly(ADP-ribose) polymerase and their potential therapeutic targets" Expert Opinion on Therapeutic Patents, vol. 12(7), pages 1047-1071 (2002).

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

Notice of References Cited

Application/Control No.

10/772,235

Applicant(s)/Patent Under
Reexamination
LI ET AL.

Examiner

Zachary C. Tucker

Art Unit

1624

Page 2 of 3

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Al-Dabbagh and Smith, "Species differences in oxidative drug metabolism: some basic considerations." Archives of toxicology. Supplement. Archiv fur Toxikologie. supplement, vol. 7, pages 219-231 (1984). —
	V	Hans Bundgaard, Design of Prodrugs, page 1. © 1985 Elsevier Science Publishers. —
	W	Richard B. Silverman, The Organic Chemistry of Drug Design and Drug Action, pages 352-400. © 1992 Academic Press, Inc. —
	X	Sieglitz et al, "3-Hydroxyfluoroanthene-1-, -2-, and -10-carboxylic acids" Chemische Berichte, vol. 95, pages 3013-3029 (1962), as abstracted by CAPLUS.

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

Notice of References Cited	Application/Control No. 10/772,235	Applicant(s)/Patent Under Reexamination LI ET AL.	
	Examiner Zachary C. Tucker	Art Unit 1624	Page 3 of 3

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Worker, Charlotte "A novel PARP inhibitor, ion channel modulation and AD therapies" IDrugs, vol. 2(9), pages 859-860 (1999).
	V	
	W	
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.